VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

Judd W. Moul, MD
Published: Friday, Oct 30, 2015



Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.



Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x